Board of Directors

 

Jeff Williams

Jeff is Chief Executive Officer at Clinipace Worldwide [read bio]

Kenneth B. Lee, Jr., Board Chairman

Ken is a general partner for HPV III at Hatteras Venture Partners and is involved in deal sourcing, investment decisions and implementing exit strategies. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Ken is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm's national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.

Ken is a nationally-recognized financial matters expert and serves on the boards of Maxygen, Inc. (MAXY), Pozen, Inc. (POZN) and Inspire Pharmaceuticals, Inc. (ISPH), where he is Chairman of the Board. Until April 2009, Ken was also on the board of CV Therapeutics, which was acquired by Gilead Sciences, Inc.

John Crumpler

John co-founded Hatteras Venture Partners in 2000 after a successful career as a technology entrepreneur. At Hatteras, John is a General Partner and is responsible for the firm's investments in health care and life science information technology, and overall fund operations. He was founder and CEO of E-Comm, Inc. in 1991, a software development and services firm specializing in remote and mobile computing that was acquired by XcelleNet. John ran the services division of XcelleNet until Sterling Commerce acquired XcelleNet for $243 million. He served on the board of Synthematix and currently serves on the board of Clinipace Worldwide where he has helped lead the transformation of Clinipace from a pure software company to a full-service digital CRO.

John served on the N. C. Economic Development Board, the state's Clean Water Management Trust Fund board of directors, and currently serves on the board of the Council for Entrepreneurial Development and as a trustee of the University of North Carolina School of the Arts. Throughout his career he has been active in government and public policy at the state and federal levels. He holds a BA in History from Harvard University.

Melissa Daniels

Melissa is a Managing Principal at Morgan Stanley Expansion Capital and the Co-Head and Managing Member of Morgan Stanley Venture Partners. Melissa has been an active growth equity investor and board member in numerous software, healthcare service, healthcare IT and medical device companies. Melissa’s current and recent board positions include Arcadian Health, Clinipace Worldwide, Discoverx, EKOS, National Healing, PeopleClick and SouthernCare. Prior to joining Morgan Stanley, Melissa held operational and management roles in private companies, and also served as staff on a subcommittee of the US House of Representatives.

Melissa earned a BA in Economics from the University of North Carolina at Chapel Hill and earned her MBA from the University of California at Berkeley.

Jeremy Mario

Jeremy serves as Principal, Private Equity Investments for Mario Family Partners and has more than ten years experience in the pharmaceutical and health care fields, ranging from clinical development services to marketing and research. For the past nine years he has managed the private equity portfolio of Mario Family Partners, a diversified asset management company that specializes in early-stage biotech ventures. Jeremy has extensive expertise in helping early stage companies refine business plans and capitalization goals.